Close Menu

NEW YORK (GenomeWeb) – Bristol-Myers Squibb and Boston Medical Center are collaborating on a multi-year research study on biomarkers that indicate sensitivity and resistance to standard-of-care checkpoint inhibitors.

The goal of the study is to identify prognostic and predictive immuno-oncology biomarkers across different cancers. The researchers will explore not only tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.